Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer

Lucy J. Schmidt, Donald J. Tindall

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease. Article from the Special issue on Targeted Inhibitors.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalJournal of Steroid Biochemistry and Molecular Biology
Issue number1-2
StatePublished - May 2011


  • 5 Alpha-reductase inhibition
  • Chemoprevention
  • Prostate disease

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Endocrinology
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer'. Together they form a unique fingerprint.

Cite this